MMP-9 levels in elderly patients with cognitive dysfunction after carotid surgery
| Autor: | Anna Granat, Susie S. Lee, Eric J. Heyer, John G. Gaudet, Gene T. Yocum, Maya Mikami, E. Sander Connolly |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Urology Carotid endarterectomy Neuropsychological Tests Matrix metalloproteinase Article Carotid surgery Postoperative Complications Physiology (medical) Diabetes mellitus medicine Humans Aged Endarterectomy Endarterectomy Carotid Tissue Inhibitor of Metalloproteinase-1 business.industry Matrix metalloproteinase 9 General Medicine Plasma levels Middle Aged medicine.disease Neurovascular bundle Surgery Matrix Metalloproteinase 9 Neurology Female Neurology (clinical) Cognition Disorders business |
| Zdroj: | Journal of Clinical Neuroscience. 17:436-440 |
| ISSN: | 0967-5868 |
| DOI: | 10.1016/j.jocn.2009.07.103 |
| Popis: | Approximately 25% of elderly patients scheduled for carotid endarterectomy (CEA) develop post-operative cognitive dysfunction (CD). We tested the hypothesis that the plasma levels of matrix metalloproteinase 9 (MMP-9) are predictive of moderate to severe CD after CEA. A total of 73 patients were prospectively enrolled in this Institutional Review Board approved study. Plasma samples were obtained at baseline and day 1 post-surgery. We measured the plasma concentrations of both MMP-9 and its inhibitor, tissue inhibitor of metalloproteinases 1 (TIMP-1). We estimated the MMP-9 activity by calculating the MMP-9:TIMP-1 ratio. The cognitive performance day 1 post-surgery was quantified with z-scores, using a control group who were undergoing spinal surgery. The criteria used to define CD was performance of ≥ 1.5 standard deviations worse than the control group; approximately 19% of eligible patients developed CD. Compared to patients without CD, this group had both higher total (81.66 ± 12.25 ng/mL versus [vs.] 43.18 ± 4.44 ng/mL, p = 0.005) and activity (0.88 ± 0.24 ng/mL vs. 0.54 ± 0.06 ng/mL, p = 0.003) MMP-9 levels at baseline. All of the results were adjusted for age, diabetes and neurovascular symptoms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect